<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    <!-- Primary SEO -->
    <title>Pediatric Cancer Legislation Tracker | Give Kids a Chance Act & More â€” The 4% Project</title>
    <meta name="description" content="Track key pediatric cancer legislation including the Mikaela Naylon Give Kids a Chance Act (signed into law February 3, 2026), the Fairness to Kids with Cancer Act, and the RACE for Children Act. Bill numbers, status, and direct Congress.gov links.">
    <meta name="keywords" content="Mikaela Naylon Give Kids a Chance Act, H.R. 1262, pediatric cancer legislation, Fairness to Kids with Cancer Act, RACE for Children Act, pediatric cancer bills Congress, childhood cancer law 2026">
    <meta name="author" content="The 4% Project">
    <meta name="robots" content="index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1">
    <link rel="canonical" href="https://the4percentproject.org/legislation.html">

    <!-- Open Graph -->
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://the4percentproject.org/legislation.html">
    <meta property="og:site_name" content="The 4% Project">
    <meta property="og:title" content="Mikaela Naylon Give Kids a Chance Act Signed Into Law â€” February 3, 2026">
    <meta property="og:description" content="After years of near-misses, the landmark pediatric cancer bill became law. Track it and the next battles: the Fairness to Kids with Cancer Act and RACE Act expansion.">
    <meta property="og:image" content="https://images.unsplash.com/photo-1631815588090-d4bfec5b1ccf?w=1200&h=630&fit=crop">
    <meta property="og:image:width" content="1200">
    <meta property="og:image:height" content="630">
    <meta property="og:locale" content="en_US">

    <!-- Twitter / X -->
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@4PercentProject">
    <meta name="twitter:title" content="Mikaela Naylon Give Kids a Chance Act Signed Into Law â€” February 3, 2026">
    <meta name="twitter:description" content="After years of near-misses, the landmark pediatric cancer bill became law. Track it and the next battles: the Fairness to Kids with Cancer Act and RACE Act expansion.">
    <meta name="twitter:image" content="https://images.unsplash.com/photo-1631815588090-d4bfec5b1ccf?w=1200&h=630&fit=crop">

    <!-- AEO: Structured Data â€” BreadcrumbList -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {"@type":"ListItem","position":1,"name":"Home","item":"https://the4percentproject.org/"},
        {"@type":"ListItem","position":2,"name":"Pediatric Cancer Legislation Tracker: Laws Won and","item":"https://the4percentproject.org/legislation.html"}
      ]
    }
    </script>

    <!-- AEO: Structured Data â€” Article -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "Article",
      "headline": "Pediatric Cancer Legislation Tracker: Laws Won and Battles Ahead",
      "description": "Track key pediatric cancer legislation including the Mikaela Naylon Give Kids a Chance Act (signed into law February 3, 2026), the Fairness to Kids with Cancer Act, and the RACE for Children Act. Bill numbers, status, and direct Congress.gov links.",
      "url": "https://the4percentproject.org/legislation.html",
      "publisher": {
        "@type": "Organization",
        "name": "The 4% Project",
        "url": "https://the4percentproject.org"
      },
      "dateModified": "2026-02-23"
    }
    </script>

    <!-- AEO: Structured Data â€” FAQPage -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "FAQPage",
      "mainEntity": [
        {"@type":"Question","name":"Was the Mikaela Naylon Give Kids a Chance Act signed into law?","acceptedAnswer":{"@type":"Answer","text":"Yes. The Mikaela Naylon Give Kids a Chance Act (H.R. 1262) was signed into law by President Trump on February 3, 2026, as part of the FY2026 Consolidated Appropriations Act. It reauthorizes the FDA Rare Pediatric Disease Priority Review Voucher program through 2029 and authorizes the FDA to require pediatric combination drug trials."}},
        {"@type":"Question","name":"Who is Mikaela Naylon?","acceptedAnswer":{"@type":"Answer","text":"Mikaela Naylon was a 16-year-old from Colorado who was diagnosed with osteosarcoma (a rare bone cancer) in 2020. Despite relapsing four times and undergoing a below-knee amputation, multiple surgeries, and radiation, she spent her final weeks advocating for the Give Kids a Chance Act by meeting with lawmakers in Washington and continuing by Zoom as her health declined. She died on October 29, 2025. Congress dedicated the signed law in her name."}},
        {"@type":"Question","name":"What is the Fairness to Kids with Cancer Act?","acceptedAnswer":{"@type":"Answer","text":"The Fairness to Kids with Cancer Act (H.R. 5405) would mandate that NCI funding for childhood cancer research be proportional to the pediatric share of the U.S. population â€” increasing pediatric research funding from 4% to approximately 22% over time. The bill has bipartisan support but is currently in committee and requires additional co-sponsors to advance."}}
      ]
    }
    </script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Libre+Baskerville:wght@400;700&family=Work+Sans:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        * { margin:0; padding:0; box-sizing:border-box; }
        :root {
            --primary:#d62828; --primary-dark:#9d0208; --primary-light:#f77f00;
            --accent:#003049; --accent-light:#669bbc;
            --text-dark:#1a1a1a; --text-gray:#4a4a4a;
            --bg-cream:#fdfcf8; --bg-light:#ffffff;
            --border:#e8e4dc; --shadow:rgba(0,0,0,0.08);
            --green-dark:#1b4332; --green-mid:#2d6a4f; --green-light:#d8f3dc;
        }
        body { font-family:'Work Sans',sans-serif; line-height:1.6; color:var(--text-dark); background:var(--bg-cream); overflow-x:hidden; }
        h1,h2,h3,h4,h5,h6 { font-family:'Libre Baskerville',serif; line-height:1.2; font-weight:700; }
        nav { background:var(--bg-light); box-shadow:0 2px 10px var(--shadow); position:sticky; top:0; z-index:1000; }
        .nav-container { max-width:1200px; margin:0 auto; padding:1rem 2rem; display:flex; justify-content:space-between; align-items:center; }
        .logo { font-family:'Libre Baskerville',serif; font-size:1.5rem; font-weight:700; color:var(--primary); text-decoration:none; }
        .nav-links { display:flex; gap:2rem; list-style:none; }
        .nav-links a { color:var(--text-dark); text-decoration:none; font-weight:500; transition:color 0.3s ease; }
        .nav-links a:hover { color:var(--primary); }
        .nav-links a.active { color:var(--primary); border-bottom:2px solid var(--primary); }
        .mobile-menu-btn { display:none; background:none; border:none; font-size:1.5rem; cursor:pointer; }
        .container { max-width:1200px; margin:0 auto; padding:0 2rem; }
        .page-hero { background:linear-gradient(135deg,rgba(0,48,73,0.95) 0%,rgba(102,155,188,0.92) 100%); color:white; padding:5rem 2rem 4rem; }
        .page-hero h1 { font-size:clamp(2rem,4vw,3rem); margin-bottom:1rem; }
        .page-hero p { font-size:1.2rem; font-weight:300; max-width:700px; opacity:0.9; }
        section { padding:5rem 0; }
        .section-header { text-align:center; margin-bottom:4rem; }
        .section-header h2 { font-size:clamp(1.8rem,3vw,2.5rem); margin-bottom:1rem; color:var(--accent); }
        .section-header p { font-size:1.1rem; color:var(--text-gray); max-width:700px; margin:0 auto; }

        /* Bill Cards */
        .bill-card { background:white; border-radius:16px; padding:2.5rem; box-shadow:0 4px 20px var(--shadow); margin-bottom:2rem; border-left:6px solid var(--primary); }
        .bill-card.law { border-left-color:var(--green-mid); }
        .bill-card.active { border-left-color:var(--accent); }
        .bill-card.stalled { border-left-color:#888; }
        .bill-meta { display:flex; flex-wrap:wrap; gap:0.75rem; align-items:center; margin-bottom:1.25rem; }
        .tag { display:inline-block; padding:0.3rem 0.9rem; border-radius:50px; font-size:0.78rem; font-weight:700; letter-spacing:0.3px; }
        .tag-law { background:var(--green-light); color:var(--green-dark); }
        .tag-active { background:#dbeafe; color:#1e40af; }
        .tag-pending { background:#fff3cd; color:#856404; }
        .tag-stalled { background:#f1f5f9; color:#475569; }
        .bill-number { font-size:0.8rem; font-weight:600; color:var(--text-gray); background:#f1f5f9; padding:0.3rem 0.75rem; border-radius:50px; }
        .bill-card h3 { font-size:1.4rem; color:var(--accent); margin-bottom:1rem; }
        .bill-card h3 a { color:inherit; text-decoration:none; border-bottom:2px solid var(--accent-light); transition:border-color 0.2s; }
        .bill-card h3 a:hover { border-color:var(--primary); color:var(--primary); }
        .bill-card p { color:var(--text-gray); margin-bottom:0.85rem; line-height:1.7; }
        .bill-card p:last-child { margin-bottom:0; }
        .bill-card strong { color:var(--text-dark); }
        .btn-sm { display:inline-flex; align-items:center; gap:0.4rem; padding:0.55rem 1.1rem; border-radius:50px; font-weight:600; text-decoration:none; font-size:0.85rem; transition:all 0.25s ease; margin-top:1rem; margin-right:0.5rem; }
        .btn-law { background:var(--green-mid); color:white; }
        .btn-law:hover { background:var(--green-dark); transform:translateY(-2px); }
        .btn-bill { background:var(--accent); color:white; }
        .btn-bill:hover { background:#004a73; transform:translateY(-2px); }
        .btn-outline { background:transparent; color:var(--accent); border:2px solid var(--accent); }
        .btn-outline:hover { background:var(--accent); color:white; transform:translateY(-2px); }

        /* Spotlight: Mikaela */
        .mikaela-spotlight { background:linear-gradient(135deg,var(--green-dark),var(--green-mid)); color:white; border-radius:20px; padding:3rem; margin-bottom:3rem; position:relative; overflow:hidden; }
        .mikaela-spotlight::before { content:'âœ“'; position:absolute; right:2rem; top:1.5rem; font-size:5rem; opacity:0.12; font-weight:900; }
        .signed-badge { display:inline-flex; align-items:center; gap:0.5rem; background:rgba(255,255,255,0.2); border:1px solid rgba(255,255,255,0.4); border-radius:50px; padding:0.4rem 1rem; font-size:0.85rem; font-weight:700; margin-bottom:1.5rem; }
        .mikaela-spotlight h3 { font-size:1.8rem; margin-bottom:1rem; }
        .mikaela-spotlight p { opacity:0.92; line-height:1.7; margin-bottom:1rem; }
        .mikaela-spotlight .highlight-stat { font-size:2.5rem; font-family:'Libre Baskerville',serif; font-weight:700; color:#a7f3d0; margin-bottom:0.25rem; }
        .mikaela-spotlight .highlight-label { font-size:0.85rem; opacity:0.8; margin-bottom:2rem; }
        .stat-row { display:grid; grid-template-columns:repeat(3,1fr); gap:1.5rem; margin:2rem 0; }
        .stat-item { text-align:center; background:rgba(255,255,255,0.1); border-radius:12px; padding:1.25rem; }
        .stat-item .num { font-size:1.8rem; font-family:'Libre Baskerville',serif; font-weight:700; color:#a7f3d0; }
        .stat-item .lbl { font-size:0.8rem; opacity:0.8; margin-top:0.25rem; }
        .btn-white { background:white; color:var(--green-dark); font-weight:700; }
        .btn-white:hover { background:#f0fdf4; transform:translateY(-2px); }

        /* Champions / Blockers */
        .two-col { display:grid; grid-template-columns:1fr 1fr; gap:2rem; margin:3rem 0; }
        .champion-card { background:white; border-radius:16px; padding:2.5rem; box-shadow:0 4px 20px var(--shadow); }
        .champion-card h3 { font-size:1.2rem; color:var(--green-mid); margin-bottom:1.25rem; }
        .blocker-card h3 { color:var(--primary); }
        .rep-item { display:flex; gap:0.75rem; align-items:flex-start; padding:0.65rem 0; border-bottom:1px solid #f1f5f9; font-size:0.9rem; }
        .rep-item:last-child { border-bottom:none; }
        .rep-star { color:var(--green-mid); font-size:1.1rem; flex-shrink:0; margin-top:0.1rem; }
        .rep-x { color:var(--primary); font-size:1rem; flex-shrink:0; margin-top:0.1rem; }

        /* Action box */
        .action-box { background:var(--accent); color:white; border-radius:16px; padding:3rem; text-align:center; margin:3rem 0; }
        .action-box h3 { font-size:2rem; margin-bottom:1rem; }
        .action-box p { font-size:1.1rem; opacity:0.9; margin-bottom:2rem; max-width:650px; margin-left:auto; margin-right:auto; }
        .btn-lg { display:inline-block; padding:1rem 2.5rem; border-radius:50px; font-weight:600; text-decoration:none; transition:all 0.3s ease; font-size:1rem; margin:0.5rem; }
        .btn-white-lg { background:white; color:var(--accent); }
        .btn-white-lg:hover { background:#f0f0f0; transform:translateY(-2px); }
        .btn-primary-lg { background:var(--primary); color:white; }
        .btn-primary-lg:hover { background:var(--primary-dark); transform:translateY(-2px); }

        footer { background:var(--accent); color:white; padding:3rem 2rem; text-align:center; }
        footer a { color:var(--primary-light); text-decoration:none; }
        @media (max-width:768px) {
            .nav-links { display:none; } .mobile-menu-btn { display:block; }
            .two-col { grid-template-columns:1fr; }
            .stat-row { grid-template-columns:1fr 1fr; }
            .mikaela-spotlight { padding:2rem; }
        }
    </style>
</head>
<body>
<nav>
    <div class="nav-container">
        <a href="index.html" class="logo">The 4% Project</a>
        <ul class="nav-links">
            <li><a href="index.html">Home</a></li>
            <li><a href="funding-discrepancy.html">Funding Crisis</a></li>
            <li><a href="doctor-pay.html">Doctor Pay Gap</a></li>
            <li><a href="legislation.html" class="active">Legislation & Lobbying</a></li>
            <li><a href="how-we-help.html">How We Help</a></li>
        </ul>
        <button class="mobile-menu-btn">â˜°</button>
    </div>
</nav>

<main>
    <div class="page-hero">
        <div class="container">
            <h1>Legislation & Lobbying</h1>
            <p>Real change requires legislative action. Here's what's now law, what's still being fought, who's fighting for kids, and how you can make your voice heard.</p>
        </div>
    </div>

    <section>
        <div class="container">
            <div class="section-header">
                <h2>Laws Won & Battles Ahead</h2>
                <p>Tracking the legislation that defines the fight for children with cancer</p>
            </div>

            <!-- SIGNED INTO LAW -->
            <div class="mikaela-spotlight">
                <div class="signed-badge">âœ“ SIGNED INTO LAW â€” February 3, 2026</div>
                <h3>Mikaela Naylon Give Kids a Chance Act</h3>
                <p>After years of near-missesâ€”blocked by Rand Paul in the final hour of the 118th Congress, then stalled again by Bernie Sanders in December 2025â€”the Mikaela Naylon Give Kids a Chance Act was included in the FY2026 Consolidated Appropriations Act and signed into law by President Trump on February 3, 2026.</p>
                <p>The law is named for Mikaela Naylon, a 16-year-old from Colorado who spent her final weeksâ€”even as she entered hospiceâ€”on Zoom calls with lawmakers advocating for this bill. She died on October 29, 2025, hours after Sen. John Hickenlooper called her. Congress dedicated the Act in her name.</p>

                <div class="stat-row">
                    <div class="stat-item">
                        <div class="num">313</div>
                        <div class="lbl">Bipartisan House Co-sponsors</div>
                    </div>
                    <div class="stat-item">
                        <div class="num">60+</div>
                        <div class="lbl">PRVs Awarded Since 2012</div>
                    </div>
                    <div class="stat-item">
                        <div class="num">2029</div>
                        <div class="lbl">PRV Program Extended Through</div>
                    </div>
                </div>

                <p><strong style="color:#a7f3d0;">What it does:</strong> Reauthorizes the FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program through 2029, giving pharmaceutical companies a financial incentive to develop drugs for rare pediatric diseases. Authorizes the FDA to require pediatric trials of drug <em>combinations</em>â€”closing the loophole that let companies study single drugs in children while withholding combination therapies. Extends NIH pediatric research funding through fiscal year 2027 and strengthens FDA oversight of required post-market pediatric studies.</p>

                <a href="https://www.congress.gov/bill/119th-congress/house-bill/1262" target="_blank" class="btn-sm btn-white" style="display:inline-flex;align-items:center;gap:0.4rem;padding:0.65rem 1.25rem;border-radius:50px;font-weight:700;font-size:0.9rem;text-decoration:none;">
                    ðŸ“‹ View H.R. 1262 on Congress.gov
                </a>
                <a href="https://mccaul.house.gov/media-center/press-releases/house-passes-mccauls-landmark-childhood-cancer-legislation" target="_blank" class="btn-sm" style="display:inline-flex;align-items:center;gap:0.4rem;padding:0.65rem 1.25rem;border-radius:50px;font-weight:700;font-size:0.9rem;text-decoration:none;background:rgba(255,255,255,0.2);color:white;border:1px solid rgba(255,255,255,0.4);margin-left:0.75rem;">
                    ðŸ”— McCaul Press Release
                </a>
            </div>

            <!-- ACTIVE / PENDING BILLS -->
            <div class="bill-card active">
                <div class="bill-meta">
                    <span class="tag tag-active">Active in Congress</span>
                    <span class="bill-number">H.R. 5405 â€” 119th Congress</span>
                </div>
                <h3><a href="https://www.congress.gov/bill/118th-congress/house-bill/5405" target="_blank">Fairness to Kids with Cancer Act</a></h3>
                <p>This landmark bill would mandate that NCI funding for childhood cancer research be proportional to the pediatric share of the U.S. populationâ€”targeting a minimum of 22% over time, up from the current 4%. It directly addresses the core structural problem: federal funding has never been tied to population need.</p>
                <p><strong>Status:</strong> Introduced with bipartisan support. Currently in committee. Needs broader co-sponsor support to advance to a floor vote.</p>
                <p><strong>Why it matters:</strong> Without a mandate, incremental progress remains vulnerable to budget pressures. This bill would make proportional funding the law of the land.</p>
                <a href="https://www.congress.gov/bill/118th-congress/house-bill/5405" target="_blank" class="btn-sm btn-bill">ðŸ“‹ View on Congress.gov</a>
            </div>

            <div class="bill-card">
                <div class="bill-meta">
                    <span class="tag tag-law">Enacted Law (2017 / Ongoing)</span>
                    <span class="bill-number">P.L. 115-52 (FDA Reauthorization Act, Sec. 504)</span>
                </div>
                <h3><a href="https://www.congress.gov/bill/115th-congress/house-bill/1231" target="_blank">RACE for Children Act</a></h3>
                <p>The Research to Accelerate Cures and Equity (RACE) for Children Act, signed into law in 2017 as part of the FDA Reauthorization Act, requires pharmaceutical companies developing adult cancer drugs to also study their use in pediatric patients when the drug targets a molecule relevant to pediatric cancer. It has meaningfully increased the number of planned pediatric cancer studies.</p>
                <p><strong>Current status:</strong> In force. Expansion proposals would broaden requirements to more drug classes and require pediatric oncology investment as a condition of federal research grants. Still facing pharmaceutical industry opposition.</p>
                <a href="https://www.congress.gov/bill/115th-congress/house-bill/1231" target="_blank" class="btn-sm btn-bill">ðŸ“‹ RACE Act (H.R. 1231)</a>
                <a href="https://www.gao.gov/products/gao-23-105947" target="_blank" class="btn-sm btn-outline">ðŸ“Š GAO Progress Report</a>
            </div>

            <div class="bill-card stalled">
                <div class="bill-meta">
                    <span class="tag tag-pending">Proposed â€” Seeking Sponsors</span>
                </div>
                <h3>Pediatric Oncologist Loan Forgiveness Act</h3>
                <p>Would extend federal student loan forgiveness to physicians who commit to practicing pediatric oncology for a minimum of 5 years, directly targeting the compensation gap that discourages medical students from entering the specialty. With average medical school debt exceeding $200,000 and a lifetime earnings gap of $3â€“6 million vs. adult oncology, the pipeline to pediatric cancer care is structurally broken.</p>
                <p><strong>Status:</strong> Proposed language being developed. Seeking primary sponsors in both chambers. This represents a key legislative priority for The 4% Project.</p>
                <a href="https://www.congress.gov/members/find-your-member" target="_blank" class="btn-sm btn-bill">Find Your Rep to Advocate</a>
            </div>

            <!-- Champions + Blockers -->
            <div class="two-col">
                <div class="champion-card">
                    <h3>ðŸŸ¢ Champions for Kids</h3>
                    <p style="font-size:0.9rem;color:var(--text-gray);margin-bottom:1rem;">Representatives with consistent records of sponsoring and advancing pediatric cancer legislation:</p>
                    <div class="rep-item"><span class="rep-star">â˜…</span><div><strong>Rep. Michael McCaul (R-TX)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Founder, Childhood Cancer Caucus. Lead sponsor, Give Kids a Chance Act & RACE Act</span></div></div>
                    <div class="rep-item"><span class="rep-star">â˜…</span><div><strong>Sen. Markwayne Mullin (R-OK)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Senate lead for Give Kids a Chance Act. Fought for 11 years to get it signed</span></div></div>
                    <div class="rep-item"><span class="rep-star">â˜…</span><div><strong>Sen. Michael Bennet (D-CO)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Senate co-lead, Give Kids a Chance Act. Long-time pediatric cancer appropriations advocate</span></div></div>
                    <div class="rep-item"><span class="rep-star">â˜…</span><div><strong>Rep. Doris Matsui (D-CA)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Co-sponsor, Give Kids a Chance Act and RACE Act. Research funding champion</span></div></div>
                    <div class="rep-item"><span class="rep-star">â˜…</span><div><strong>Rep. Debbie Dingell (D-MI)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Key co-sponsor, Give Kids a Chance Act. Bipartisan health champion</span></div></div>
                </div>
                <div class="champion-card blocker-card">
                    <h3>ðŸ”´ Where Progress Has Stalled</h3>
                    <p style="font-size:0.9rem;color:var(--text-gray);margin-bottom:1rem;">Pediatric cancer legislation has repeatedly been blocked by a small number of senators using procedural holds:</p>
                    <div class="rep-item"><span class="rep-x">âœ—</span><div><strong>Sen. Rand Paul (R-KY)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Objected to Give Kids a Chance Act via unanimous consent at 11:50 PM on the last night of the 118th Congress â€” killing it hours before passage</span></div></div>
                    <div class="rep-item"><span class="rep-x">âœ—</span><div><strong>Sen. Bernie Sanders (I-VT)</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Blocked the Give Kids a Chance Act in December 2025, demanding it be paired with unrelated community health center funding</span></div></div>
                    <div class="rep-item"><span class="rep-x">âœ—</span><div><strong>Pharmaceutical Industry Lobbying</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">Ongoing opposition to mandatory pediatric drug testing requirements and RACE Act expansion</span></div></div>
                    <div class="rep-item"><span class="rep-x">âœ—</span><div><strong>Budget Committee Resistance</strong><br><span style="font-size:0.85rem;color:var(--text-gray);">New mandatory spending requirements face structural opposition regardless of merit</span></div></div>
                </div>
            </div>

            <div class="action-box">
                <h3>Make Your Voice Heard</h3>
                <p>Personal calls and letters from constituents move legislation forwardâ€”especially on lower-visibility issues like pediatric cancer funding. The Fairness to Kids with Cancer Act needs co-sponsors. Your representative's office can be the difference.</p>
                <a href="https://www.congress.gov/members/find-your-member" target="_blank" class="btn-lg btn-white-lg">Find Your Representatives</a>
                <a href="how-we-help.html" class="btn-lg btn-primary-lg">How The 4% Project Helps</a>
            </div>
        </div>
    </section>
</main>

<footer>
    <div class="container">
        <p style="font-weight:600;font-size:1.1rem;margin-bottom:1rem;">Let's put a dent in the universe. Together.</p>
        <p>Â© 2026 The 4% Project | Fighting for fair funding in pediatric cancer research</p>
    </div>
</footer>
</body>
</html>
